Author

K. Budagyan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. C. Cannon· 1 shared A. M. Kurimchak· 1 shared C. Uribe-Alvarez· 1 shared D. Araiza-Olivera· 1 shared J. Chernoff· 1 shared J. S. Duncan· 1 shared K. Q. Cai· 1 shared S. Peri· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. C. Cannon

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

A. C. Cannon, K. Budagyan, C. Uribe-Alvarez, A. M. Kurimchak, D. Araiza-Olivera, K. Q. Cai, S. Peri, Y. Zhou, J. S. Duncan, J. Chernoff

This study identifies CDK9 as a novel therapeutic target in RAC1P29S-mutant melanoma and shows that combining CDK9 inhibition with anti-PD-1 therapy enhances tumor suppression.

bioRxiv · Jun 27, 2023 · PreprintCancer Biology